Ephrin-A1/EFNA1 蛋白, Human (AAH32698.1, HEK293, His)

Ephrin-A1/EFNA1 Protein is a member of the A-type ephrin family of cell surface proteins that function as ligands for the A-type Eph receptor tyrosine kinase family (EphA2). EFNA1 exerts its function largely through interactions with EphA2. EFNA1 exists in a soluble form as well as a glycophosphatidylinositol (GPI) membrane attached form. EFNA1 acts as a membrane-bound, GPI-anchored protein capable of mediating juxtacrine signalling and requiring membrane attachment or clustering/oligomerization. EFNA1 is a novel TNF-inducible protein. EFNA1 efficiently binds to the EphA8 receptor expressed in NIH3T3 fibroblasts. EFNA1 stimulates PI3K activity via direct interaction of EphA2 with the p85 subunit of PI3K. EFNA1 can both inhibit and stimulate oncogenesis, depending on the cellular context^[1][2][3]. Ephrin-A1/EFNA1 Protein, Human (AAH32698.1, HEK293, His) is the recombinant human-derived Ephrin-A1/EFNA1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Ephrin-A1/EFNA1 Protein, Human (AAH32698.1, HEK293, His) is 164 a.a., with molecular weight of 25-30 kDa.

肝配蛋白家族由八个成员组成，根据其细胞膜附着方式分为 A 和 B 亚类。肝配蛋白-A1-A5 通过糖基磷脂酰肌醇 (GPI) 部分与膜连接，而肝配蛋白-B1-B3 通过跨膜结构域锚定并包含细胞质尾部。由于其膜定位，肝配蛋白能够参与正向和反向信号传导^[1]。
肝配蛋白-A1 的 G-H 环是一个由 15 个氨基酸组成的高度保守区域，连接 G 和 H β 链，被插入 EphA2 表面的通道中，形成异二聚体、1:1 配体/受体复合物。肝配蛋白-A1 的配体结合会诱导 EphA2 自磷酸化并与 c-Cbl 相互作用，然后导致受体内化和降解^[1]。
Ephrin-A1 激活 EphA2 会减少细胞对 ECM 的附着，并抵消多种细胞类型中的整合素信号传导，导致 Rac 介导的 Rho 活性上调。Ephrin-A1 刺激 EphA2 会抑制基础和 EGF 诱导的 MAPK 活性^[1]。
膜附着形式的 EFNA1 的过度表达会抑制 HeLa 细胞的 3D 生长，但不会抑制 2D 生长。内源性 EFNA1 的敲低或全长 EFNA1 的过表达导致 EPHA2 从细胞表面重新定位到细胞与细胞接触的部位。可溶性 EFNA1 的过度表达会导致更多的 EPHA2 分布在细胞表面，远离细胞与细胞的接触，并促进 HeLa 细胞的生长^[2]。
EFNA1 与 CD4+ T 细胞结合可刺激基质细胞衍生因子 1α (SDF-1α) 和巨噬细胞炎症蛋白 3β (MIP3beta) 介导的趋化作用^[3]。

1.Immobilized Human Ephrin-A1-His at 10 μg/mL (100 μl/well) can bind Human EphA2-Fc.The ED₅₀ for this effect is 12.71 ng/mL.
2.Measured by its binding ability in a functional ELISA. When Recombinant Human (rh) EphA2 is coated at 2 μg/mL (100 μL/well), the concentration of rhEphrin-A1 Fc Chimera that produces 50% of the optimal binding response is found to be approximately 4.998 ng/mL.

• 
  Measured by its binding ability in a functional ELISA. When Recombinant Human (rh) EphA2 is coated at 2 μg/mL (100 μL/well), the concentration of rhEphrin-A1 Fc Chimera that produces 50% of the optimal binding response is found to be approximately 4.998 ng/mL.

Human

HEK293

C-6*His

AAH32698.1/NP_004419.2 (D19-S182)

1942  [NCBI]

DRHTVFWNSSNPKFRNEDYTIHVQLNDYVDIICPHYEDHSVADAAMEQYILYLVEHEEYQLCQPQSKDQVRWQCNRPSAKHGPEKLSEKFQRFTPFTLGKEFKEGHSYYYISKPIHQHEDRCLRLKVTVSGKITHSPQAHDNPQEKRLAADDPEVRVLHSIGHS

25-30 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.2 μm filtered solution of 20 mM Tris-HCl, 4% Trehalose, 4% Mannitol, 0.02% Tween 80, pH 8.0 or 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.